Next Article in Journal
Use of Cyclo-Oxygenase Inhibitors Is Not Associated with Clinical Relapse in Inflammatory Bowel Disease: A Case-Control Study
Next Article in Special Issue
Ecology of Anti-Biofilm Agents I: Antibiotics versus Bacteriophages
Previous Article in Journal / Special Issue
Antifungal Activity of 14-Helical β-Peptides against Planktonic Cells and Biofilms of Candida Species
Open AccessCommentary

Prospects for Anti-Biofilm Pharmaceuticals

Center for Biofilm Engineering and Department of Chemical and Biological Engineering, 366 EPS Building, Montana State University, Bozeman, MT 59717, USA
Academic Editor: Dacheng Ren
Pharmaceuticals 2015, 8(3), 504-511;
Received: 1 July 2015 / Revised: 21 August 2015 / Accepted: 24 August 2015 / Published: 27 August 2015
(This article belongs to the Special Issue Microbial Biofilms)
PDF [653 KB, uploaded 31 August 2015]


This commentary highlights several avenues currently being pursued in research labs to the development of new anti-biofilm pharmaceuticals. There is a real need for alternative therapeutic modalities for treating the persistent infections that sometimes form on implanted medical devices or compromised niches within the body. Strategies being researched include discovering new antimicrobial agents that kill microorganisms in biofilms more effectively than do existing antibiotics, designing drugs that block microbial adhesion or interfere with intercellular communication, developing chemistries to disperse biofilms, and combining agents with different mechanisms of action. Though the need is great, the pathway to commercialization of new drugs is steep. One possible streamlined approach to navigating the regulatory approval process is to repurpose old drugs, a strategy that a few groups have shown can yield agents with anti-biofilm properties. View Full-Text
Keywords: biofilm; drug; antibiotic biofilm; drug; antibiotic
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Stewart, P.S. Prospects for Anti-Biofilm Pharmaceuticals. Pharmaceuticals 2015, 8, 504-511.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top